Guidance Capital Inc. Takes Position in NeoGenomics, Inc. (NASDAQ:NEO)

Guidance Capital Inc. purchased a new stake in NeoGenomics, Inc. (NASDAQ:NEO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 32,030 shares of the medical research company’s stock, valued at approximately $528,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Versant Capital Management Inc increased its stake in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares in the last quarter. Quarry LP acquired a new position in NeoGenomics during the 3rd quarter worth approximately $40,000. Blue Trust Inc. boosted its position in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after acquiring an additional 987 shares during the last quarter. KBC Group NV boosted its position in NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after acquiring an additional 1,127 shares during the last quarter. Finally, FMR LLC boosted its position in NeoGenomics by 7.6% during the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after acquiring an additional 931 shares during the last quarter. 98.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NEO has been the subject of a number of recent research reports. Bank of America upped their price target on NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Jefferies Financial Group assumed coverage on NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a report on Friday, January 10th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, The Goldman Sachs Group cut their price objective on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, NeoGenomics has an average rating of “Moderate Buy” and an average price target of $20.20.

Insiders Place Their Bets

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the completion of the sale, the general counsel now owns 37,129 shares in the company, valued at $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

NeoGenomics Stock Up 0.5 %

NeoGenomics stock opened at $13.95 on Wednesday. The stock’s 50 day moving average is $16.40 and its 200 day moving average is $15.69. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. NeoGenomics, Inc. has a one year low of $12.13 and a one year high of $19.11.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The business had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.06) earnings per share. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.16 EPS for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.